Molecularly targeted therapy in renal cell carcinoma

References

• Bukowski RM. Cytokine therapy for metastatic renal cell carcinoma. Semin. Urol. Oncol. 19(2), 148–154 (2001).
   PubMedGoogle Scholar
• Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nature Genet. 7(1), 85–90 (1994).
   PubMed Web of Science ®Google Scholar
• Shuin T, Kondo K, Torigoe S et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res. 54(11), 2852–2855 (1994).
   PubMed Web of Science ®Google Scholar
• Herman JG, Latif F, Weng Y et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl Acad. Sci. USA 91(21), 9700–9704 (1994).
   PubMed Web of Science ®Google Scholar
• Gnarra JR, Lerman MI, Zbar B, Linehan WM. Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Semin. Oncol. 22(1), 3–8 (1995).
   PubMed Web of Science ®Google Scholar
• Kondo K, Yao M, Yoshida M et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer 34(1), 58–68 (2002).
   PubMed Web of Science ®Google Scholar
• Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG Jr. Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science 269(5229), 1444–1446 (1995).
   PubMed Web of Science ®Google Scholar
• Maxwell PH, Wiesener MS, Chang GW et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399(6733), 271–275 (1999).
   PubMed Web of Science ®Google Scholar
• Cockman ME, Masson N, Mole DR et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275(33), 25733–25741 (2000).
   PubMed Web of Science ®Google Scholar
• Ivan M, Haberberger T, Gervasi DC et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc. Natl Acad. Sci. USA 99(21), 13459–13464 (2002).
   PubMed Web of Science ®Google Scholar
• Pugh CW, Ratcliffe PJ. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Semin. Cancer Biol. 13(1), 83–89 (2003).
   PubMed Web of Science ®Google Scholar
• Jaakkola P, Mole DR, Tian YM et al. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292(5516), 468–472 (2001).
   PubMed Web of Science ®Google Scholar
• Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl Acad. Sci. USA 93(20), 10595–10599 (1996).
   PubMed Web of Science ®Google Scholar
• Kourembanas S, Morita T, Liu Y, Christou H. Mechanisms by which oxygen regulates gene expression and cell–cell interaction in the vasculature. Kidney Int. 51(2), 438–443 (1997).
   PubMedGoogle Scholar
• Wiesener MS, Munchenhagen PM, Berger I et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1α in clear cell renal carcinomas. Cancer Res. 61(13), 5215–5222 (2001).
   PubMed Web of Science ®Google Scholar
• Knebelmann B, Ananth S, Cohen HT, Sukhatme VP. Transforming growth factor α is a target for the von Hippel-Lindau tumor suppressor. Cancer Res. 58(2), 226–231 (1998).
   PubMed Web of Science ®Google Scholar
• Gunaratnam L, Morley M, Franovic A et al. Hypoxia inducible factor activates the transforming growth factor-α/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J. Biol. Chem. 278(45), 44966–44974 (2003).
   PubMed Web of Science ®Google Scholar
• de Paulsen N, Brychzy A, Fournier MC et al. Role of transforming growth factor-α in von Hippel-Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc. Natl Acad. Sci. USA 98(4), 1387–1392 (2001).
   PubMed Web of Science ®Google Scholar
• Maxwell PH, Pugh CW, Ratcliffe PJ. The pVHL–hIF-1 system. A key mediator of oxygen homeostasis. Adv. Exp. Med. Biol. 502, 365–376 (2001).
   PubMedGoogle Scholar
• Stadler WM, Richards JM, Vogelzang NJ. Serum interleukin-6 levels in metastatic renal cell cancer: correlation with survival but not an independent prognostic indicator. J. Natl Cancer Inst. 84(23), 1835–1836 (1992).
   PubMedGoogle Scholar
• Negrier S, Perol D, Menetrier-Caux C et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6-from the Groupe Francais d'Immunotherapie. J. Clin. Oncol. 22(12), 2371–2378 (2004).
   PubMed Web of Science ®Google Scholar
• Grabmaier K, A de Weijert MC , Verhaegh GW, Schalken JA, Oosterwijk E. Strict regulation of CAIX(G250/MN) by HIF-1α in clear cell renal cell carcinoma. Oncogene 23(33), 5624–5631 (2004).
   PubMed Web of Science ®Google Scholar
• Vissers JL, De Vries IJ, Engelen LP et al. Renal cell carcinoma-associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen-DR molecules to CD4(+) T-lymphocytes. Int. J. Cancer 100(4), 441–444 (2002).
   PubMed Web of Science ®Google Scholar
• Latif F, Tory K, Gnarra J et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260(5112), 1317–1320 (1993).
   PubMed Web of Science ®Google Scholar
• Brauch H, Hoeppner W, Jahnig H et al. Sporadic pheochromocytomas are rarely associated with germline mutations in the vhl tumor suppressor gene or the ret protooncogene. J. Clin. Endocrinol. Metab. 82(12), 4101–4104 (1997).
   PubMedGoogle Scholar
• Clifford SC, Prowse AH, Affara NA, Buys CH, Maher ER. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 22(3), 200–209 (1998).
   PubMed Web of Science ®Google Scholar
• Kenck C, Wilhelm M, Bugert P, Staehler G, Kovacs G. Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas. J. Pathol. 179(2), 157–161 (1996).
   PubMed Web of Science ®Google Scholar
• Bard RH, Mydlo JH, Freed SZ. Detection of tumor angiogenesis factor in adenocarcinoma of kidney. Urology 27(5), 447–450 (1986).
   PubMedGoogle Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23(5), 1011–1027 (2005).
   PubMed Web of Science ®Google Scholar
• Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146(5), 1029–1039 (1995).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Keyt B. Vascular endothelial growth factor: basic biology and clinical implications. EXS 79, 209–232 (1997).
   PubMedGoogle Scholar
• Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103(2), 159–165 (1999).
   PubMed Web of Science ®Google Scholar
• Jain RK, Safabakhsh N, Sckell A et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc. Natl Acad. Sci. USA 95(18), 10820–10825 (1998).
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Lee SW, Detmar M, Ajioka I, Dvorak HF. Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells. Oncogene 14(17), 2025–2032 (1997).
   PubMed Web of Science ®Google Scholar
• ••Seminal manuscript that was at the forefront in providing evidence of the active mechanisms of regulation of the microvasculature.
   Google Scholar
• Seliger B, Menig M, Lichtenfels R et al. Identification of markers for the selection of patients undergoing renal cell carcinoma-specific immunotherapy. Proteomics 3(6), 979–990 (2003).
   PubMed Web of Science ®Google Scholar
• Bleumer I, Knuth A, Oosterwijk E et al. A Phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br. J. Cancer 90(5), 985–990 (2004).
   PubMed Web of Science ®Google Scholar
• Brouwers A, Mulders P, Oosterwijk E et al. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies. Cancer Biother. Radiopharm. 19(4), 466–477 (2004).
   PubMed Web of Science ®Google Scholar
• Divgi CR, O'Donoghue JA, Welt S et al. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J. Nucl. Med. 45(8), 1412–1421 (2004).
   PubMed Web of Science ®Google Scholar
• Brouwers A, Verel I, Van Eerd J et al. PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats. Cancer Biother. Radiopharm. 19(2), 155–163 (2004).
   PubMed Web of Science ®Google Scholar
• Liu MY, Poellinger L, Walker CL. Upregulation of hypoxia-inducible factor 2α in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene. Cancer Res. 63(10), 2675–2680 (2003).
   PubMed Web of Science ®Google Scholar
• Parry L, Maynard JH, Patel A et al. Analysis of the TSC1 and TSC2 genes in sporadic renal cell carcinomas. Br. J. Cancer 85(8), 1226–1230 (2001).
   PubMedGoogle Scholar
• Hudson CC, Liu M, Chiang GG et al. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 22(20), 7004–7014 (2002).
   PubMed Web of Science ®Google Scholar
• Zundel W, Schindler C, Haas-Kogan D et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 14(4), 391–396 (2000).
   PubMed Web of Science ®Google Scholar
• Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4(2), 147–158 (2003).
   PubMed Web of Science ®Google Scholar
• Brugarolas J, Kaelin WG Jr. Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell 6(1), 7–10 (2004).
   PubMed Web of Science ®Google Scholar
• Presta LG, Chen H, O'Connor SJ et al. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57(20), 4593–4599 (1997).
   PubMed Web of Science ®Google Scholar
• Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized antiVEGF antibody in vitro. Angiogenesis 7(4), 335–345 (2004).
   PubMedGoogle Scholar
• Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349(5), 427–434 (2003).
   PubMed Web of Science ®Google Scholar
• Yang JC. Bevacizumab for patients with metastatic renal cancer: an update. Clin. Cancer Res. 10(18 Pt 2), S6367–S6370 (2004).
   Web of Science ®Google Scholar
• Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL. Cancer and Leukemia Group B 90206: a randomized Phase III trial of interferon-α or interferon-α plus antivascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin. Cancer Res. 10(8), 2584–2586 (2004).
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Cunningham HT, Carbone DP. IL-12 and mutant P53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer. J. Immunother. Emphasis Tumor Immunol. 19(6), 414–418 (1996).
   PubMedGoogle Scholar
• Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. 5(10), 2963–2970 (1999).
   PubMed Web of Science ®Google Scholar
• Sun L, Liang C, Shirazian S et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 46(7), 1116–1119 (2003).
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9(1), 327–337 (2003).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, Michaelson MD et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. 23(16S), 4508 (2005).
   Google Scholar
• Joneson T, Bar-Sagi D. Ras effectors and their role in mitogenesis and oncogenesis. J. Mol. Med. 75(8), 587–593 (1997).
   PubMed Web of Science ®Google Scholar
• Bar-Sagi D. A Ras by any other name. Mol. Cell. Biol. 21(5), 1441–1443 (2001).
   PubMed Web of Science ®Google Scholar
• Lyons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer 8(3), 219–225 (2001).
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64(19), 7099–7109 (2004).
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Eisen T, Stadler WM et al. Final findings from a Phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. 23(16S), 4544 (2005).
   Google Scholar
• Escudier B, Szczylik C, Eisen T et al. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. 23(16S), 4510 (2005).
   Web of Science ®Google Scholar
• Inai T, Mancuso M, Hashizume H et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. 165(1), 35–52 (2004).
   PubMed Web of Science ®Google Scholar
• Rini B, Rixe O, Bukowski R et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates antitumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). Proc. Am. Soc. Clin. Oncol. 23(16S), 4509 (2005).
   PubMedGoogle Scholar
• Fabian MA, Biggs WH III, Treiber DK et al. A small molecule–kinase interaction map for clinical kinase inhibitors. Nature Biotechnol. 23(3), 329–336 (2005).
   PubMed Web of Science ®Google Scholar
• Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M, Suthanthiran M. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int. 63(3), 917–926 (2003).
   PubMedGoogle Scholar
• Atkins MB, Hidalgo M, Stadler WM et al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22(5), 909–918 (2004).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20(1), 289–296 (2002).
   PubMed Web of Science ®Google Scholar
• Visapaa H, Seligson D, Huang Y et al. Ki67, gelsolin and PTEN expression in sarcomatoid renal tumors. Urol. Res. 30(6), 387–389 (2003).
   PubMedGoogle Scholar
• Smith K, Gunaratnam L, Morley M, Franovic A, Mekhail K, Lee S. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. Cancer Res. 65(12), 5221–5230 (2005).
   PubMed Web of Science ®Google Scholar
• Prewett M, Rothman M, Waksal H, Feldman M, Bander NH, Hicklin DJ. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin. Cancer Res. 4(12), 2957–2966 (1998).
   PubMed Web of Science ®Google Scholar
• Weber KL, Doucet M, Price JE, Baker C, Kim SJ, Fidler IJ. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Res. 63(11), 2940–2947 (2003).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Amato R, Todd M et al. Phase II trial of anti-epidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest. New Drugs 21(1), 99–101 (2003).
   PubMed Web of Science ®Google Scholar
• Drucker B, Bacik J, Ginsberg M et al. Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Invest. New Drugs 21(3), 341–345 (2003).
   PubMed Web of Science ®Google Scholar
• Dawson NA, Guo C, Zak R et al. A Phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin. Cancer Res. 10(23), 7812–7819 (2004).
   PubMed Web of Science ®Google Scholar
• Viloria-Petit A, Crombet T, Jothy S et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 61(13), 5090–5101 (2001).
   PubMed Web of Science ®Google Scholar
• Spigel DR, Hainsworth JD, Sosman JA et al. Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): update of a Phase II multicenter trial. Proc. Am. Soc. Clin. Oncol. 23(16S), 4540 (2005).
   Google Scholar
• Gemmill RM, Zhou M, Costa L, Korch C, Bukowski RM, Drabkin HA. Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma. Br. J. Cancer 92(12), 2266–2277 (2005).
   PubMed Web of Science ®Google Scholar